Investigation of King Pharmaceuticals, Inc. concerning its prescription drug Avinza CII (morphine sulfate extended-release capsules).
King Pharmaceuticals was recently informed by the Food and Drug Administration ("FDA") that the government agency believed that King Pharmaceuticals was falsely and/or misleadingly advertising Avinza. Avinza is prescribed to treat moderate to severe chronic pain.
The FDA has stated that some of the advertising for "Avinza is false or misleading in that it presents efficacy claims for Avinza but fails to communicate and minimizes risks associated with its use, fails to present the limitations to its approved indication, and presents unsubstantiated efficacy claims."
Do not change medications without first consulting your doctor.
Name (Stock Symbol)
King Pharmaceutical, Inc. (KG)
King Pharmaceutical, Inc. is a pharmaceutical company.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.